
https://www.science.org/content/blog-post/silently-affecting-immune-system
# Silently Affecting the Immune System? (April 2017)

## 1. SUMMARY
This commentary discusses a Nature Chemical Biology study that screened 1,402 small-molecule drugs for unintended immunomodulatory effects using peripheral blood mononuclear cells (PBMCs) from a single donor. The researchers discovered that roughly 10% of tested compounds showed immune-modulating activity, with kinase inhibitors emerging as a particularly interesting class.

The key finding highlighted in the article was crizotinib (Xalkori), an FDA-approved receptor tyrosine kinase inhibitor, which unexpectedly increased interactions between CD11c+ cells and CD3+ cells and elevated MHC-II expression on CD11c+ cells. The research traced this effect to crizotinib binding to MST1R/RON receptor at 25 nM affinity. This suggested that some of crizotinib's antitumor activity might stem from immunomodulatory effects rather than solely from its known kinase inhibition, potentially broadening its therapeutic applications to immuno-oncology combinations.

## 2. HISTORY
The crizotinib immunomodulation finding did not translate into substantial clinical adoption or new FDA approvals in the years following the 2017 publication. While the mechanistic insights about MST1R/RON binding were scientifically interesting, several factors limited real-world impact:

Crizotinib remained primarily used for its original oncology indications (ALK-positive and ROS1-positive non-small cell lung cancer) rather than expanding into immuno-oncology combinations as a standalone immunomodulator. No major clinical trials emerged combining crizotinib with checkpoint inhibitors like pembrolizumab or nivolumab based on these findings.

The broader proposal to incorporate immunomodulatory assays into routine drug screening has not become standard practice in pharmaceutical development as of 2024. While target-based screening and safety profiling remain crucial, systematic immune-system-wide screening has not been adopted as a routine gate in drug discovery pipelines.

The study's single-donor PBMC approach, while elegant for reducing background variability, also limits generalizability. Pharmaceutical companies continue to focus on intended mechanisms of action rather than systematic fishing expeditions for off-target immune effects.

## 3. PREDICTIONS
• **Prediction**: Crizotinib would become a valuable addition to immuno-oncology therapies.  
**Reality**: Crizotinib did not become widely adopted in immuno-oncology. No major combination trials with checkpoint inhibitors emerged, and it remains primarily indicated for ALK/ROS1-positive NSCLC.

• **Prediction**: Immunomodulatory assays would become routine in drug development screening.  
**Reality**: Systematic immunomodulatory screening has not become standard practice in pharmaceutical development. While safety/toxicology panels include immune-related end points, large-scale exploratory immune profiling of all investigational compounds is not routine.

• **Prediction**: The receptor tyrosine kinase inhibitor class would reveal more immunomodulatory effects than previously recognized.  
**Reality**: Some additional kinase inhibitors have been found to have immune-related effects (e.g., certain mTOR inhibitors), but this has not fundamentally changed how the class is viewed clinically. Kinase inhibitors remain primarily classified and prescribed based on their intended kinase targets rather than secondary immune effects.

• **Prediction**: The ~10% hit rate for immunomodulation would justify expanded screening efforts.  
**Reality**: While scientifically interesting, this hit rate did not drive systematic changes in pharmaceutical screening strategies. Development priorities remain focused on intended mechanisms and conventional safety profiling over comprehensive immune-effect mapping.

## 4. INTEREST
Rating: **3/10**

The article addressed scientifically valid questions about off-target drug effects, but the findings had minimal practical impact on clinical practice or drug development paradigms. While the crizotinib mechanism discovery was intellectually interesting, it did not lead to significant therapeutic advances or changes in how drugs are developed.


----
_model_params = {'model': 'nex-agi/deepseek-v3.1-nex-n1:free', 'input': '20170426-silently-affecting-immune-system.txt', 'reasoning': {'effort': 'high'}, 'text': {'verbosity': 'medium'}, 'prompt-template': 'prompt-template-2'}_